177 related articles for article (PubMed ID: 19881341)
1. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances.
Asmar M; Holst JJ
Curr Opin Endocrinol Diabetes Obes; 2010 Feb; 17(1):57-62. PubMed ID: 19881341
[TBL] [Abstract][Full Text] [Related]
2. [Incretin and bone].
Yamada Y
Clin Calcium; 2009 Sep; 19(9):1312-7. PubMed ID: 19721203
[TBL] [Abstract][Full Text] [Related]
3. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes.
Gautier JF; Choukem SP; Girard J
Diabetes Metab; 2008 Feb; 34 Suppl 2():S65-72. PubMed ID: 18640588
[TBL] [Abstract][Full Text] [Related]
4. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic actions of the incretin hormones.
McIntosh CH; Widenmaier S; Kim SJ
Vitam Horm; 2010; 84():21-79. PubMed ID: 21094896
[TBL] [Abstract][Full Text] [Related]
6. The Role of Incretins on Insulin Function and Glucose Homeostasis.
Holst JJ; Gasbjerg LS; Rosenkilde MM
Endocrinology; 2021 Jul; 162(7):. PubMed ID: 33782700
[TBL] [Abstract][Full Text] [Related]
7. Biology of incretins: GLP-1 and GIP.
Baggio LL; Drucker DJ
Gastroenterology; 2007 May; 132(6):2131-57. PubMed ID: 17498508
[TBL] [Abstract][Full Text] [Related]
8. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
[TBL] [Abstract][Full Text] [Related]
9. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
10. New physiological effects of the incretin hormones GLP-1 and GIP.
Asmar M
Dan Med Bull; 2011 Feb; 58(2):B4248. PubMed ID: 21299928
[TBL] [Abstract][Full Text] [Related]
11. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
Pacini G; Thomaseth K; Ahrén B
Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
[TBL] [Abstract][Full Text] [Related]
12. Incretin actions beyond the pancreas: lessons from knockout mice.
Yabe D; Seino Y
Curr Opin Pharmacol; 2013 Dec; 13(6):946-53. PubMed ID: 24095602
[TBL] [Abstract][Full Text] [Related]
13. Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models.
Renner S; Blutke A; Streckel E; Wanke R; Wolf E
J Pathol; 2016 Jan; 238(2):345-58. PubMed ID: 26455904
[TBL] [Abstract][Full Text] [Related]
14. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
15. Central regulation of glucose-dependent insulinotropic polypeptide secretion.
Yavropoulou MP; Yovos JG
Vitam Horm; 2010; 84():185-201. PubMed ID: 21094900
[TBL] [Abstract][Full Text] [Related]
16. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides.
Rehfeld JF
Acta Physiol (Oxf); 2011 Apr; 201(4):405-11. PubMed ID: 21392266
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
18. The biology of incretin hormones.
Drucker DJ
Cell Metab; 2006 Mar; 3(3):153-65. PubMed ID: 16517403
[TBL] [Abstract][Full Text] [Related]
19. Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide.
Meier JJ; Nauck MA
Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):587-606. PubMed ID: 15533777
[TBL] [Abstract][Full Text] [Related]
20. [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)].
Kluz J; Adamiec R
Postepy Hig Med Dosw (Online); 2006; 60():15-23. PubMed ID: 16407790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
